"Long COVID": More than a quarter of COVID-19 patients still symptomatic after 6 months

In a new study of adults from the general population who were infected with COVID-19 in 2020, more than a quarter report not having fully recovered after six to eight months. Those findings are described this week in the open-access journal PLOS ONE by Milo Puhan and colleagues at the University of Zurich, Switzerland.

While initial public health responses to the SARS-CoV-2 virus focused on reducing the acute burden of COVID-19, a growing body of evidence indicates that the infection can also result in longer-term physical and mental health consequences. These long-term consequences, currently referred to as "post-COVID-19 syndrome" or "Long Covid" are of increasing concern for healthcare systems.

In the new study, researchers recruited 431 participants from within the contact tracing system in Zurich, Switzerland. All participants had tested positive for SARS-CoV-2 between February and August 2020, and completed an online questionnaire about their health a median of 7.2 months after their diagnosis. Symptoms had been present at diagnosis in 89% of the participants and 19% were initially hospitalized. Compared to individuals not participating in the study, participants were younger--with an average age of 47.

Overall, 26% of participants reported that they had not fully recovered at six to eight months after initial COVID-19 diagnosis. 55% reported symptoms of fatigue, 25% had some degree of shortness of breath, and 26% had symptoms of depression. A higher percentage of females and initially hospitalized patients reported not having recovered compared to males and non-hospitalized individuals. A total of 40% of participants reported at least one general practitioner visit related to COVID-19 after their acute illness. The authors say that their findings underscore the need for the timely planning of resources and patient services for post-COVID-19 care.

The authors add: "This cohort study based on a respresentative, population-based sample of SARS-CoV-2 infected individuals found that 26% did not fully recover within 6-8 months after diagnosis and 40% had at least one further healthcare contact related to COVID-19. These findings underline the need for the timely planning of healthcare resources and services tailored to the needs of individuals suffering from post-COVID-19 syndrome."

Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al.
Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study.
PLoS ONE 2021. doi: 10.1371/journal.pone.0254523

Most Popular Now

Lilly and Lycia Therapeutics enter into strategic …

Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, devel...

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

Gut bacteria and flavonoid-rich foods are linked a…

Flavonoid-rich foods, including berries, apples, pears and wine, appear to have a positive effect on blood pressure levels, an association that is partially explained by ...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...